Literature DB >> 19618288

Modulation of the immune response to HBV vaccination by hemodialysis membranes.

Fatih Dede1, Ayla Yıldız, Deniz Aylı, Nujen Colak, Ali Rıza Odabaş, Hadim Akoğlu, Erdal Eskioğlu, Adrian Covic.   

Abstract

INTRODUCTION: Seroconversion response to Hepatitis B virus (HBV) vaccination is limited in uremic patients because of impaired humoral and cellular immune activity. Recent studies show that high-flux (HF) hemodialysis (HD) membranes can improve T cell functions and decrease the proinflammatory cytokine activation more effectively than low-flux (LF) membranes. In regard to HF membranes may have immune modulator effects; we compared the antibody responses to hepatitis B vaccination between HF HD and LF HD membranes.
METHODS: One thousand four hundred and eight patients on HD programmed for 4 h three times a week at three different centers with HF or LF membranes were scanned. Anti-HBs levels of these patients who were vaccinated with recombinant DNA HBV vaccine on the 0, 1st, 2nd and 6th month from the beginning were recorded on the 0, 3rd, 6th, 9th and 12th month of vaccination schedule.
RESULTS: Seroconversion rate was 84.2% in HF group and 52.7% in LF group on the 6th month (P < 0.01). Ratio of the patients who had >100 IU/l antibody titers in HF group was 22.8%, while it was 10.9% in LF group (P < 0.01). Also on the 9th, 12th and 24th month; seroconversion rates in HF group were higher than LF group: 91.1-70.9% (P < 0.05), 95.0-81.8% (P < 0.05), 92.1-83.7% (P > 0.05), respectively. Ratio of the patients who did not show any seroconversion was higher in LF group than HF group; on the 6th month as 15.8-47.3% (P < 0.001), on the 9th month 8.9-29.1% (P < 0.05), on the 12th month as 5.0-18.2% (P < 0.05), and on the 24th month as 7.9-16.4% (P > 0.05), respectively.
CONCLUSION: We showed that ratio of anti-HBs seroconversion response to hepatitis B vaccination in patients receiving HD with HF membranes was higher than LF membranes. This finding suggests that HF membranes may improve immune modulator effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19618288     DOI: 10.1007/s11255-009-9616-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  22 in total

Review 1.  Hepatitis B vaccine and dialysis: current issues.

Authors:  F Fabrizi; P Martin
Journal:  Int J Artif Organs       Date:  2001-10       Impact factor: 1.595

2.  Effects of high-flux hemodialysis on oxidant stress.

Authors:  Richard A Ward; Rosemary Ouseph; Kenneth R McLeish
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

3.  Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn.

Authors:  J T Daugirdas
Journal:  Adv Ren Replace Ther       Date:  1995-10

4.  Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study.

Authors:  R Vanholder; S Ringoir; A Dhondt; R Hakim
Journal:  Kidney Int       Date:  1991-02       Impact factor: 10.612

5.  Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy.

Authors:  C E Stevens; H J Alter; P E Taylor; E A Zang; E J Harley; W Szmuness
Journal:  N Engl J Med       Date:  1984-08-23       Impact factor: 91.245

6.  Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination.

Authors:  I Tsouchnikas; E Dounousi; K Xanthopoulou; S Papakonstantinou; V Thomoglou; D Tsakiris
Journal:  Clin Nephrol       Date:  2007-10       Impact factor: 0.975

7.  Evaluation of hemodialysis adequacy using online Kt/V and single-pool variable-volume urea Kt/V.

Authors:  Alicja E Grzegorzewska; Wojciech Banachowicz
Journal:  Int Urol Nephrol       Date:  2008-07-01       Impact factor: 2.370

8.  Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients.

Authors:  M Girndt; H Köhler; E Schiedhelm-Weick; J F Schlaak; K H Meyer zum Büschenfelde; B Fleischer
Journal:  Kidney Int       Date:  1995-02       Impact factor: 10.612

9.  Non-responsiveness to hepatitis B vaccination in haemodialysis patients: association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition.

Authors:  J Stachowski; M Pollok; C Barth; J Maciejewski; C A Baldamus
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

Review 10.  T cells and B cells in chronic renal failure.

Authors:  B Descamps-Latscha; L Chatenoud
Journal:  Semin Nephrol       Date:  1996-05       Impact factor: 5.299

View more
  3 in total

Review 1.  Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 2.  Dendritic Cell Dysfunction in Patients with End-stage Renal Disease.

Authors:  Ji Ung Kim; Miyeon Kim; Sinae Kim; Tam Thanh Nguyen; Eunhye Kim; Siyoung Lee; Soohyun Kim; Hyunwoo Kim
Journal:  Immune Netw       Date:  2017-06-20       Impact factor: 6.303

3.  Immune response to influenza vaccination in ESRD patients undergoing hemodialysis vs. hemodiafiltration.

Authors:  Arkom Nongnuch; Wattanachai Ngampongpan; Sirawat Srichatrapimuk; Artit Wongsa; Sutheera Thongpraphai; Chompunuch Boonarkart; Nutaporn Sanmeema; Malinee Chittaganpitch; Prasert Auewarakul; Boonrat Tassaneetrithep; Andrew Davenport; Angsana Phuphuakrat
Journal:  PLoS One       Date:  2020-02-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.